Volatile metabonomic profiling in urine to detect novel biomarkers for B‑cell non‑Hodgkin's lymphoma

• Published in: Oncology letters Vol. 15; no. 5; pp. 7806 - 7816
• Main Authors: Hua, Qingling, Wang, Lin, Liu, Chan, Han, Lingling, Zhang, Yazhong, Liu, Hu
• Format: Journal Article
• Language: English
• Published: Greece Spandidos Publications 01.05.2018; Spandidos Publications UK Ltd; D.A. Spandidos
• Subjects: Acids; Biological markers; Biomarkers; Cancer; Care and treatment; Development and progression; Disease; Health aspects; Innovations; Laboratories; Lymphoma; Medical imaging; Medical screening; Metabolism; Metabolites; NMR; Non-Hodgkin's lymphomas; Nuclear magnetic resonance; Oncology; Prostate; Standard deviation; Urine; Beijing China; China; volatile metabolites; screening; B-cell non-Hodgkin lymphoma; monitoring; urine
• ISSN: 1792-1074; 1792-1082
• DOI: 10.3892/ol.2018.8352

To date, there have been a limited number of useful biomarkers for the screening and monitoring of B-cell non-Hodgkin's lymphoma (B-NHL), which leads to the impetus to discover novel biomarkers for the disease. In the present study, gas chromatography-mass spectrometry (GC-MS) combined with head-space solid-phase micro-extraction (HS-SPME) was employed to analyze the volatile metabolites in the urine samples of 131 subjects. The subjects were divided into 4 main groups: Aggressive B-NHL, indolent B-NHL, benign lymphatic diseases patients and healthy volunteers. The differences of the concentrations of the potential biomarkers among the groups were assessed by non-parametric Wilcoxon's test. The ability of the potential biomarkers to discriminate between the four aforementioned groups was evaluated by receiver operating characteristic curves (ROC). The present study indicated that 4-heptanone, 2-methylpyrazine, 2-methylbutanal, 2,6-dimethyl-7-octen-2-ol and decanoic acid may serve as potential biomarkers for B-NHL. The area under the curve (AUC) values of single potential biomarker ranged from 0.634 to 0.901. The diagnostic models established with combined biomarkers exhibited higher diagnostic values (AUC, 0.824-0.968) compared with the models established with single biomarkers. The present study indicated that urinary volatile metabolites might be potential biomarkers for screening and monitoring of B-NHL.